Holen Sie sich die Stockscreener-App
0.63
0.79%
-0.005
Handel nachbörslich:
.62
-0.01
-1.59%
Schlusskurs vom Vortag:
$0.635
Offen:
$0.62
24-Stunden-Volumen:
23,039
Relative Volume:
0.35
Marktkapitalisierung:
$11.07M
Einnahmen:
$52.58M
Nettoeinkommen (Verlust:
$-3.28M
KGV:
-3.2693
EPS:
-0.1927
Netto-Cashflow:
$-2.53M
1W Leistung:
-0.63%
1M Leistung:
-12.94%
6M Leistung:
-37.62%
1J Leistung:
-44.76%
1-Tages-Spanne:
$0.62
$0.6351
1-Wochen-Bereich:
$0.615
$0.6499
52-Wochen-Spanne:
$0.607
$1.6481
Iridex Corp Stock (IRIX) Company Profile
Firmenname
Iridex Corp
Sektor
Branche
Telefon
(650) 940-4700
Adresse
1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA
Compare IRIX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
0.63 | 10.98M | 52.58M | -3.28M | -2.53M | -0.1927 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2017-11-03 | Fortgesetzt | ROTH Capital | Buy |
| 2016-12-21 | Eingeleitet | ROTH Capital | Buy |
| 2016-01-26 | Eingeleitet | Singular Research | Buy |
| 2007-01-03 | Eingeleitet | First Albany | Buy |
Iridex Corp Aktie (IRIX) Neueste Nachrichten
IRIDEX (IRIX) CFO buys 7,900 more shares - Stock Titan
IRIDEX (IRIX) CFO adds 2,354 shares in open-market buy - Stock Titan
CFO now holds 175,052 shares after Iridex Corp (IRIX) stock buy - Stock Titan
IRIDEX Received Notice of Noncompliance - TradingView
IRIDEX (NASDAQ:IRIX): What Is Driving Penny Stock Attention? - Kalkine Media
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15% - Yahoo Finance
IRIDEX (IRIX) Latest Quarter: The EPS Result Is Below Expectation in the Current Update; Latest Reaction: Shares Close 0.81% Lower at the CloseOperating Margin Analysis - dars.gov.et
Iridex Q2 revenue misses estimate as loss widens to $0.07 - scanx.trade
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 - GuruFocus
IRIX Looks 45.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Earnings call transcript: IRIDEX misses Q2 2026 estimates as cash flow turns positive - Investing.com South Africa
IRIDEX Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Is IRIDEX Corp (IRIX) Positioned for Growth After Q2 Earnings Mi - GuruFocus
IRIDEX Q2 Revenue Falls 7% as Retina Weakness Offsets Glaucoma Growth - Minichart
Form 8K IRIDEX Corporation For: 18 August By Investing.com - Investing.com Canada
Full Transcript: Iridex Q2 2026 Earnings Call - Benzinga
IRIDEX Corp reports results for the quarter ended June 30Earnings Summary - TradingView
IRIDEX CORP Q2 2026: Revenue $12.6M, EPS $(0.07) — 10-Q Summary - TradingView
IRIDEX (IRIX) glaucoma sales rise as retina revenue falls - Stock Titan
IRIDEX earnings missed by $0.05, revenue fell short of estimates - Investing.com
Iridex Reports Q2 2026 Revenue $12.6M, Net Loss $1.3M; Cyclo G6 Probe Growth Boosts Glaucoma Sales - TradingView
Iridex falls short on Q2 revenue and earnings expectations - Investing.com
Iridex falls short on Q2 revenue and earnings expectations By Investing.com - Investing.com Australia
IRIDEX ($IRIX) Releases Q2 2026 Earnings - Quiver Quantitative
Iridex Latest Results: FY26 sales guidance affirmed at $51M-$53M, below est - scanx.trade
Iridex: Q2 Earnings Snapshot - marketscreener.com
Iridex Reports Second Quarter 2026 Financial Results - GlobeNewswire
Iridex (NASDAQ:IRIX): Why Is Ophthalmic Systems And Procedure Activity in Focus Today? - Kalkine Media
IRIX|IRIDEX Corp|Price:0.880|Chg%:+0.024 - TradingKey
IRIDEX Corp (IRIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IRIDEX Corp (IRIX) Stock News Today - TradingKey
Iridex schedules Q2 business update after Aug. 18 close - Stock Titan
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026 - GlobeNewswire
IRIX Faces Continued Pressure Near Key Support Levels – IRIDEX Corporation (IRIX) at $0.86Wyckoff Distribution - dars.gov.et
IRIDEX Corp (IRIX) Institutional Confidence - TradingKey
IRIX|IRIDEX Corp|Price:0.889|Chg%:-0.002 - TradingKey
IRIDEX Corp (IRIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IRIDEX Corp (IRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IRIDEX Corp (IRIX) Cash Flow - TradingKey
IRIDEX Corp (IRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IRIX|IRIDEX Corp|Price:0.783|Chg%:-0.147 - TradingKey
IRIDEX Corp (IRIX) Income Statement - TradingKey
IRIDEX Corp (IRIX) Earnings Date & Reports & Earnings News - TradingKey
IRIDEX Corp (IRIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IRIDEX Corp (IRIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IRIDEX Corp (IRIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IRIX|IRIDEX Corp|Price:0.930|Chg%:+0.050 - TradingKey
Iridex expands EyeProGPO offering with EndoProbe handpieces - Investing.com
More Than 4,300 EyeProGPO Members Gain Preferred EndoProbe Pricing - Stock Titan
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering - Yahoo Finance
Iridex Board Warns of Legal Risks in Stealth Proxy Campaign by Major Shareholder Novel Inspiration - minichart.com.sg
Finanzdaten der Iridex Corp-Aktie (IRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iridex Corp-Aktie (IRIX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Sep 14 '26 |
Buy |
0.65 |
2,354 |
1,530 |
177,406 |
| Dizon Romeo R | Chief Financial Officer |
Sep 10 '26 |
Buy |
0.68 |
5,100 |
3,468 |
175,052 |
| Dizon Romeo R | Chief Financial Officer |
Aug 24 '26 |
Buy |
0.75 |
6,668 |
4,999 |
169,952 |
| Dizon Romeo R | Chief Financial Officer |
Jun 12 '26 |
Buy |
1.14 |
975 |
1,110 |
135,975 |
| Dizon Romeo R | Chief Financial Officer |
Jun 11 '26 |
Buy |
1.14 |
1,675 |
1,909 |
135,000 |
| Dizon Romeo R | Chief Financial Officer |
Jun 08 '26 |
Buy |
1.12 |
2,400 |
2,688 |
133,325 |
| Dizon Romeo R | Chief Financial Officer |
Jun 05 '26 |
Buy |
1.15 |
2,521 |
2,899 |
130,925 |
| Dizon Romeo R | Chief Financial Officer |
Jun 03 '26 |
Buy |
1.17 |
2,400 |
2,808 |
128,404 |
| Dizon Romeo R | Chief Financial Officer |
May 26 '26 |
Buy |
1.00 |
5,004 |
5,004 |
126,004 |
| Dizon Romeo R | Chief Financial Officer |
Mar 06 '26 |
Buy |
1.26 |
1,110 |
1,399 |
121,000 |
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):